Small human studies of DSIP have produced conflicting results for sleep. The evidence is old and limited, and there is no modern validated treatment role.
Still uncertain: Reliable benefit for insomnia, long-term safety, modern subcutaneous use or a validated treatment regimen.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Neuropeptide
Entity type
Peptide
Research focus
Sleep and neuroendocrine research
Human evidence
Human insomnia evidence is tiny, old and internally conflicting: a 1987 double-blind study reported substantial improvement, while a 1992 double-blind study found weak/inconsistent effects and considered major therapeutic benefit unlikely.
Regulatory status
Not FDA-approved; FDA lists DSIP/emideltide among substances with insufficient safety information.
Main limitations
Reliable insomnia efficacy, chronic safety, modern subcutaneous use or a validated treatment regimen.
Safety
Human safety data are sparse and dated; FDA says it lacks sufficient safety information for proposed compounded routes.
Evidence reviewed
2026-09-18
i
Human insomnia evidence is tiny, old and internally conflicting: a 1987 double-blind study reported substantial improvement, while a 1992 double-blind study found weak/inconsistent effects and considered major therapeutic benefit unlikely.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Route / formulation boundaryOlder IV research does not validate modern nasal/injectable commercial products.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. Published human insomnia-study regimen. Open descriptive regimen evidence →
Identifiers & alternate namesDSIP · Emideltide
Source depth & provenance
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
3outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
